Ardelyx, Inc., a biopharmaceutical company, announced the approval of amendments and restatements to its equity and employee stock plans following its 2024 Annual Meeting of Stockholders on June 14, 2024. The Board of Directors initially approved the changes to the 2014 Equity Incentive Award Plan and the 2014 Employee Stock Purchase Plan on April 29, 2024. These amendments, referred to as the A&R 2014 Equity Plan and the A&R ESPP respectively, were subsequently ratified by stockholders at the Annual Meeting. The meeting also saw the election of Class I director nominees, approval of executive compensation on an advisory basis, and ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The detailed proposals and voting outcomes are incorporated by reference from the Proxy Statement filed with the SEC on April 29, 2024, and supplemented on June 4, 2024.

Ardelyx, Inc., a biopharmaceutical company, announced the approval of amendments and restatements to its equity and employee stock plans following its 2024 Annual Meeting of Stockholders on June 14, 2024. The Board of Directors initially approved the changes to the 2014 Equity Incentive Award Plan and the 2014 Employee Stock Purchase Plan on April 29, 2024. These amendments, referred to as the A&R 2014 Equity Plan and the A&R ESPP respectively, were subsequently ratified by stockholders at the Annual Meeting. The meeting also saw the election of Class I director nominees, approval of executive compensation on an advisory basis, and ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The detailed proposals and voting outcomes are incorporated by reference from the Proxy Statement filed with the SEC on April 29, 2024, and supplemented on June 4, 2024.